Finding this subset is complicated by the fact that ER+/HER2− breast cancer cells likely activate HER2 only in response to endocrine therapy, making identification of these patient cohorts from diagnostic biopsies challenging. This evidence concerns the gene ESR1 and breast carcinoma.